Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 9, 2026 110 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUCCESSOR-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR ‘Scandinavian quality and Singaporean efficiency’: what the autumn statement means for... November 17, 2022 Darolutamide Extends Survival for Some People with Metastatic Prostate Cancer March 25, 2022 Do Black Lives Matter Less Than Those of Cancer Survivors? June 18, 2020 Fatiga relacionada con el cáncer: Lo que las personas con cáncer... March 2, 2021 Load more HOT NEWS FDA Approves Atezolizumab for BRAF V600 Mutation Positive Unresectable or Metastatic... ¿Qué deben saber las personas con cáncer sobre el consumo de... Cancer in My Community: Obstacles to Caring for People With Cancer... Spending Review 2021: Promising commitments, but a lot of unanswered questions
